John Lunger - Adaptimmune Therapeutics Chief Patient Supply Officer
| ADAP Stock | USD 0.70 0.04 6.06% |
Executive
Mr. John Lunger is Chief Patient Supply Officer of the Company. Prior to joining Adaptimmune in 2017, John was Head of Supply Chain and Commercial Product Supply at Merrimack Pharmaceuticals, where he led clinical and commercial supply chain as well as the cross functional supply team for Merrimack first commercial product. Earlier in his career, John held various senior manufacturing, operational, and strategy roles with VWR International, Pfizer, and Wyeth Pharmaceuticals. John previous roles include serving as a nuclear trained officer on a U.S. Navy submarine, strategic supply chain consulting with Accenture, and business development with a startup procurement services company. He holds a BS degree in Ocean Engineering from the U.S. Naval Academy and an MBA in economics and operations management from the University of Chicago Booth School of Business. since 2019.
| Age | 54 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX |
| Phone | 44 12 3543 0000 |
| Web | https://www.adaptimmune.com |
John Lunger Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Lunger against Adaptimmune Therapeutics stock is an integral part of due diligence when investing in Adaptimmune Therapeutics. John Lunger insider activity provides valuable insight into whether Adaptimmune Therapeutics is net buyers or sellers over its current business cycle. Note, Adaptimmune Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Adaptimmune Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Lunger over two months ago Acquisition by John Lunger of 2544432 shares of Adaptimmune Therapeutics at 0.14 subject to Rule 16b-3 |
Adaptimmune Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1584) % which means that it has lost $0.1584 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6504) %, meaning that it created substantial loss on money invested by shareholders. Adaptimmune Therapeutics' management efficiency ratios could be used to measure how well Adaptimmune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/26/2024, Return On Tangible Assets is likely to drop to -0.42. In addition to that, Return On Capital Employed is likely to drop to -0.69. As of 11/26/2024, Non Current Liabilities Total is likely to grow to about 178.8 M, while Total Current Liabilities is likely to drop slightly above 44.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bo Kara | Mereo BioPharma Group | N/A | |
| Erika Jones | Black Diamond Therapeutics | 39 | |
| Jason Baum | Leap Therapeutics | 45 | |
| Christopher Keenan | Pliant Therapeutics | N/A | |
| Mike JD | Pliant Therapeutics | 51 | |
| Spencer JD | PDS Biotechnology Corp | 54 | |
| Roger BSc | Aptose Biosciences | N/A | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| Jeffrey Arcara | Corvus Pharmaceuticals | N/A | |
| Huw Nash | Stoke Therapeutics | 57 | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
| Heather Boussios | Mink Therapeutics | N/A | |
| Alicia Hager | Nkarta Inc | 54 | |
| Tsveta Milanova | Agios Pharm | 47 | |
| Blake Aftab | Adicet Bio | 43 | |
| Lars MBA | PDS Biotechnology Corp | 54 | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| Clive Patience | Agios Pharm | 60 | |
| David MD | Nkarta Inc | 46 | |
| Gregory Conn | PDS Biotechnology Corp | 69 | |
| Joy Zhou | Mink Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.16 |
Adaptimmune Therapeutics Leadership Team
Elected by the shareholders, the Adaptimmune Therapeutics' board of directors comprises two types of representatives: Adaptimmune Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adaptimmune. The board's role is to monitor Adaptimmune Therapeutics' management team and ensure that shareholders' interests are well served. Adaptimmune Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adaptimmune Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kerry Sharp, Senior Council | ||
| Dennis Williams, Senior Development | ||
| Sbastien Desprez, VP Affairs | ||
| Dana Lynch, Senior Communications | ||
| Helen MBA, CoFounder Officer | ||
| Bertrand Esq, Chief Officer | ||
| Adrian Rawcliffe, Principal CEO | ||
| Juli Miller, VP Relations | ||
| Margaret Henry, Head Sec | ||
| MD BA, Chief Officer | ||
| Cintia PharmD, Chief Officer | ||
| ACA BA, Chief Officer | ||
| John Lunger, Chief Patient Supply Officer | ||
| BA ACA, Chief Officer | ||
| Joanna Brewer, Chief Officer |
Adaptimmune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adaptimmune Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | 0.54 % | ||||
| Current Valuation | 66.78 M | ||||
| Shares Outstanding | 255.88 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 60.26 % | ||||
| Number Of Shares Shorted | 5.35 M | ||||
| Price To Earning | (7.73) X |
Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
| 0.76 | ME | 23Andme Holding | PairCorr |
| 0.9 | VALN | Valneva SE ADR | PairCorr |
| 0.73 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Adaptimmune Stock
| 0.63 | KZR | Kezar Life Sciences | PairCorr |
| 0.44 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.35 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.